ERBB2 and neoplasm: According to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN guidelines) and the guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology, assessment for HER2 overexpression and/or amplification should be performed with the tumour tissues by immunohistochemistry (IHC) and fluorescence or silver in situ hybridization (FISH or SISH)7–9.